Humacyte, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HUMAW | LMAT | AORT | ANGO | 688016.SS | ELUT | |
|---|---|---|---|---|---|---|
| Market cap | — | 2.01B | 1.29B | 515.17M | 10.96B | 33.64M |
| P/E (TTM) | — | 30.8 | — | — | 18.4 | — |
| Forward P/E | — | 27.7 | 35.3 | -108.1 | 15.0 | -0.7 |
| Price/book | 0.0 | 5.1 | 2.9 | 3.2 | 2.5 | 2.1 |
| Dividend yield | — | 1.14% | — | — | 2.98% | — |
| 1-year change | — | +2.71% | −44.32% | +4.43% | −11.00% | −19.32% |
| Today | −78.05% | +9.08% | +11.56% | +4.43% | +1.76% | −6.59% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All HUMAW news ›Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped.DURHAM, N.C., Oct. 28, 2026 ... Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent…
Transcript : Humacyte, Inc., Q2 2026 Earnings Call, Aug 12, 2026
Presentation Operator MessageOperator Good morning, ladies and gentlemen, and welcome to Humacyte's second quarter 2026 earnings conference call. [Operator Instructions] As a reminder, this Transcript : Humacyte, Inc., Q2 2026 Earnings…
Humacyte, Inc. Announces Interim Results From Its V012 Phase 3 Clinical Trial Accepted For Late-Breaking Oral Presentation At ASN Kidney Week 2026
Humacyte, Inc. announced that interim results from its V012 Phase 3 clinical trial have been accepted for a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2026,... announced that interim results from its…
Humacyte, Inc. Announces Board and Committee Changes, Effective September 22, 2026
Humacyte, Inc. appointed Scott Coward and Paul Kuznik to the Board on September 22, 2026. Mr. Coward will serve as a Class I director with a term expiring in 2028, or until his earlier death,... appointed Scott Coward and Paul Kuznik to…
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.” –…
Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49
Humacyte (HUMA) provided a commercial update highlighting increasing momentum in the launch of Symvess, its FDA-approved acellular tissue engine... Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49 Humacyte (HUMA) provided a…
Humacyte, Inc. (NASDAQ:HUMA) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Read Our Latest Analysis on HUMA Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf…
Durham’s Humacyte to Present Phase 3 V012 Results for ATEV in Women on Hemodialysis at ASN Kidney Week 2026
Humacyte , a Durham, North Carolina-based commercial-stage biotechnology company developing universally implantable, bioengineered human tissues, announced on October 12, 2026 that interim results from its V012 Phase 3 clinical trial have…
Humacyte, Inc. Provides Commercial Update And Highlights Rapid Acceleration Of Symvess Adoption By Hospitals
Humacyte, Inc. provided a commercial update highlighting increasing momentum in the launch of Symvess. Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end... provided a commercial update…
Humacyte Announces First Commercial Symvess Implantation in Arizona
Humacyte announced that Symvess, acellular tissue engineered vessel-tyod, is now being used by surgeons in Arizona. The first post-Biologics License Application approval implants in the state were...
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com6
- markets.businessinsider.com5
- defenseworld.net1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.